Summary of TACTIC-E protocol published by BMC
A structured summary of a study protocol for a randomised controlled trial of Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E) has been published in the BioMed Central Journal.
The TACTIC-E clinical trial is testing whether novel therapeutic agents or novel combinations of approved agents can prevent the development of severe symptoms in patients hospitalised with strongly suspected or confirmed COVID-19. By targeting the exaggerated host response mechanisms driving the severe lung and other organ damage seen in coronavirus infection, this approach is a way of finding out whether these novel approaches are effective in treating the disease.
The treatments currently being tested in TACTIC-E are:
- EDP1815 – to modulate abnormal immune and inflammatory response to acute viral infection
- Ambrisentan in combination with Dapagliflozin – to treat respiratory, cardiovascular and renal complications from COVID-19
The platform design used by TACTIC-E provides flexibility to swap out and add in alternative treatments based on emerging data as the trial progresses.
For more information visit: CamCovidTrials
Published July 31, 2020
Latest from CCTU
New approach to treating aggressive breast cancer by Cambridge researchers shows significant improvement in survival
Researchers at NIHR Cambridge Biomedical Research Centre have shown that a new treatment approach significantly improves survival rates for patients with…
Groundbreaking Cambridge research indicates immunosuppression may help treat Parkinson’s
A pioneering trial, led from Cambridge Biomedical Research Centre, has shown that…
AI power improves cataract test tool for babies
A device invented by an Addenbrooke's eye surgeon to detect cataract in babies is set to be further improved - thanks to artificial intelligence and a team…
